Adriamycin pfs and Hepatitis - a phase IV clinical study of FDA data

Summary:

Hepatitis is reported as a side effect among people who take Adriamycin pfs (doxorubicin hydrochloride), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Cytoxan, and have Metastases to bone.

The phase IV clinical study analyzes which people have Hepatitis when taking Adriamycin pfs. It is created by eHealthMe based on reports of 6,484 people who have side effects when taking Adriamycin pfs from the FDA, and is updated regularly.

What is Adriamycin pfs?

Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users. Check the latest studies of Adriamycin pfs.

What is Hepatitis?

Hepatitis (inflammation of the liver) is found to be associated with 1,470 drugs and 1,522 conditions by eHealthMe. Check the latest studies of Hepatitis.

On Jul, 13, 2026

6,484 people reported to have side effects when taking Adriamycin pfs.
Among them, 38 people (0.59%) have Hepatitis.

Among these 38 people:

How long have people been on Adriamycin pfs when they have Hepatitis? *

What is the gender of people who have Hepatitis when taking Adriamycin pfs? *

female: 84.21 %
male: 15.79 %

What is the age of people who have Hepatitis when taking Adriamycin pfs? *

What are other drugs people take besides Adriamycin pfs? *

What are other side effects people have besides Hepatitis? *

Nausea And Vomiting: 21 people, 55.26%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 19 people, 50.00%
Gastritis (inflammation of stomach): 19 people, 50.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 19 people, 50.00%
Haematochezia (passage of stools containing blood): 19 people, 50.00%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 19 people, 50.00%
Hepatic Cyst: 19 people, 50.00%
Hepatic Lesion: 19 people, 50.00%
Hepatic Mass: 19 people, 50.00%
High Blood Cholesterol: 19 people, 50.00%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 19 people, 50.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 3 people, 7.89%
Burkitt Lymphoma (cancer of the lymphatic system): 3 people, 7.89%
Breast Cancer: 2 people, 5.26%
T-Cell Lymphoma (a blood cell cancer): 1 person, 2.63%
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin): 1 person, 2.63%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 2.63%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 1 person, 2.63%
Necrotising Fasciitis (an uncommon life-threatening soft-tissue infection): 1 person, 2.63%
Multiple Myeloma (cancer of the plasma cells): 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Adriamycin pfs and have Hepatitis?

- Check whether Hepatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adriamycin pfs:

Adriamycin pfs (6,495 reports)

Hepatitis treatments and more:

Hepatitis (31,197 reports)

Browse all side effects of Adriamycin pfs:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis:

Hepatitis (1,470 drugs)

Browse all the conditions that are associated with Hepatitis:

Hepatitis (1,522 conditions)

Related publications that referenced our studies

Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .
Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on doxorubicin hydrochloride (the active ingredients of Adriamycin pfs) and Adriamycin pfs (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.